HAVCR2 and cancer: As TIM-3 expression on cancer cells predicts response to PD-1 targeted ICI in other solid cancers (137), the consistent expression of TIM-3 on both MMRd and MMR intact tumor cells (136) suggests that ICI approaches combining PD-1 and TIM-3 (138) may provide therapeutic benefit in EC irrespective of subtype or mutational burden.